Share on StockTwits

AstraZeneca plc (NYSE:AZN)‘s stock had its “hold” rating reiterated by investment analysts at Beaufort Securities in a note issued to investors on Monday.

Shares of AstraZeneca plc (NYSE:AZN) traded down 0.67% on Monday, hitting $73.74. The stock had a trading volume of 2,317,932 shares. AstraZeneca plc has a 52-week low of $46.87 and a 52-week high of $82.68. The stock has a 50-day moving average of $75.21 and a 200-day moving average of $66.11. The company has a market cap of $92.986 billion and a price-to-earnings ratio of 45.52.

AstraZeneca plc (NYSE:AZN) last released its earnings data on Thursday, April 24th. The company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the previous year, the company posted $1.41 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. Analysts expect that AstraZeneca plc will post $4.23 EPS for the current fiscal year.

AZN has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, June 11th. Finally, analysts at BNP Paribas reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, June 5th. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $56.33.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.